SUMMARY Single intravenous doses of 10, 20, 40, and 80 mg and repeated once daily intravenous doses of 10 and 20 mg omeprazole induced a powerful and long lasting inhibition of pentagastrin stimulated gastric acid secretion (PAO) in healthy male volunteers. Single intravenous doses of 10, 20, 40, and 80 mg omeprazole inhibited PAO by 30% (p<0.01), 45% (p<001), 61% (p<001), and 80% (p<0.01), respectively when measured 1-5 h after dose, and by 20% (NS), 27% (NS), 36% (p<0.01) and 59% (p<0.01), respectively when measured 24 h after dose. Six days after repeated once daily intravenous doses of 10 and 20 mg omeprazole, PAO was inhibited by 63% (p<0-01) and 82% (p<001), respectively when measured 1-5 h after dose, and by 32% (p<0 01) and 43% (p<0-01), respectively when measured 24 h after dose. 
SUMMARY Single intravenous doses of 10, 20, 40 , and 80 mg and repeated once daily intravenous doses of 10 and 20 mg omeprazole induced a powerful and long lasting inhibition of pentagastrin stimulated gastric acid secretion (PAO) in healthy male volunteers. Single intravenous doses of 10, 20, 40 , and 80 mg omeprazole inhibited PAO by 30% (p<0.01), 45% (p<001), 61% (p<001), and 80% (p<0.01), respectively when measured 1-5 h after dose, and by 20% (NS), 27% (NS), 36% (p<0.01) and 59% (p<0.01), respectively when measured 24 h after dose. Six days after repeated once daily intravenous doses of 10 and 20 mg omeprazole, PAO was inhibited by 63% (p<0-01) and 82% (p<001), respectively when measured 1-5 h after dose, and by 32% (p<0 01) and 43% (p<0-01), respectively when measured 24 h after dose. The inhibition of PAO by 10 mg administered intravenously as a single bolus injection was comparable with the inhibition by 20 mg as a single oral dose. Repeated once daily administration of 10 mg intravenously and 20 mg orally also resulted in comparable reductions in PAO. The reduction in PAO after repeated once daily oral administration of 20 mg was comparable with the effect of a single intravenous dose of 40 mg. Terminal half lives were short, but significantly (p<005) prolonged after a single intravenous injection of 80 mg. Repeated once daily intravenous administration of 10 and 20 mg did not result in prolongation of terminal half lives. It is concluded that intravenous administration of omeprazole causes a potent and long acting inhibition of pentagastrin stimulated gastric acid secretion in man. Its potency is augmented after repeated once daily administration.
Omeprazole, a substituted benzimidazole, has been shown to possess a powerful inhibitory action on gastric acid secretion by selective inhibition of the gastric proton pump (H+/K+ATPase) in the secretory membrane of the parietal cell. ' The terminal half life (t /2) of intravenous omeprazole was determined from the individual regression lines of the log plasma concentration time curves during the elimination phase. The area under the plasma concentration time curve (AUC) was calculated using the trapezoidal rule and, in the case of intravenous administration, adding the area to infinity (last concentrationxtl/2X0-693 '). Linear regression analysis was used on data obtained in the single dose study to determine the correlation between drug induced inhibition of gastric acid (Fig. 1) .
The plasma omeprazole concentration time curves after different intravenous doses are presented in Figure 2 , and the areas under the plasma concentration-time curves and terminal half lives are presented in Table 2 . There were only small non- administration of 20 mg omeprazole was significantly lower (p<0.01) than that after repeated intravenous administration of 10 and 20 mg as well as that after a single oral dose of 20 mg.
DiscussionIntravenous administration of omeprazole induced a potent dose dependent inhibition of pentagastrin stimulated gastric acid secretion in man. Both maximal and minimal inhibition of pentagastrin stimulated PAO after single oral administration of 20 mg omeprazole were approximally equivalent to that of 10 mg omeprazole administered intravenously within the same subjects. This indicates that omeprazole has a long duration of action, which seems to be independent of the route of administration. These data are in conflict with a previous study, suggesting that single doses intravenously administered omeprazole have a shorter duration of action on intragastric acidity than expected from data obtained during oral administration. 7 The suggestion of a local effect of orally administered omeprazole is therefore not in line with the results presented in this paper. In that study, only the effect of intravenously administered omeprazole was studied and compared with data on orally administered omeprazole obtained from the literature. This may explain the apparent difference in response to oral and intravenous omeprazole in that study, because most of the data obtained with orally administered omeprazole in the literature are based on studies with repeated dosing of which a cumulative effect on the inhibition of gastric acid secretion has been reported, exaggerating the effect of single oral dose administration.' This cumulative effect after repeated oral dosing was also observed in the present study. Furthermore, this study showed that repeated once daily doses of omeprazole administered intravenously, also have a cumulative inhibitory effect on pentagastrin stimulated gastric acid secretion in man. The maximal inhibition of PAO after repeated once daily intravenous administration of 10 and 20 mg omeprazole was approximally twice as pronounced when compared with the inhibition of PAO obtained after comparable single intravenously administered doses. The maximal inhibition of PAO obtained after repeated once daily oral administration of 20 mg 
